Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
Why Immunome Stock Surged Today The oncology specialist's targeted therapies could improve thousands of lives.
Which stocks are gapping on Monday? In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Why Is IMNM Stock Rising Today? Immunome stock is on track to open at its highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type of connective tissue tumor.
These stocks are moving in today's after hours session Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Curious about the stocks that are showing activity after the closing bell on Wednesday? Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
3 Small-Cap Stocks With Big Growth Potential Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.
